WhiteLab Genomics GTM brain

WhiteLab Genomics designs and validates genomic medicine delivery systems and genetic payloads for its own pipeline and biopharma partners.

category

AI genomic medicine design

market profile

  • text: Cell and gene therapy developers need delivery vehicles and payloads optimized for biological performance, with experimental validation beyond computational predictions.
  • text: WhiteLab combines a proprietary design platform with collaborations and a strategy to develop and license bio-assets.

personas

  • title: Head of genomic medicine R&D
    pains:
    • Existing delivery vectors struggle to reach target tissues
    • Iterative construct testing consumes scarce time and research budget
  • title: Biotech chief scientific officer
    pains:
    • Promising computational designs must be validated in living systems
    • Program teams need differentiated delivery and payload assets to advance candidates
  • title: Biopharma business development lead
    pains:
    • Finding defensible external assets that fit a therapeutic pipeline
    • Aligning intellectual property and validation milestones in a partnership

icp

  • text: Pharmaceutical and biotech organizations developing cell, gene or RNA medicines with preclinical delivery challenges.
  • text: Academic and translational research institutes with relevant disease models and vector engineering programs can be scientific collaborators.

message pillars

  • text: Connect AI with genomic medicine design.
  • text: Use biological data to guide rational construct design.
  • text: Target molecular constructs for therapeutic development.

objections

  • objection: AI predictions may not translate in vivo.
    response: Review experimental and in vivo evidence for the specific construct and tissue, not only model performance.
  • objection: A partnership may complicate IP and development responsibilities.
    response: Establish asset rights, validation milestones and ownership in diligence before committing.

competitors

  • name: Dyno Therapeutics
    why: Designs gene therapy delivery capsids using AI.
  • name: Asimov
    why: Works on engineered biological systems and genetic medicine tools.
  • name: Nephrogen
    why: Uses AI and screening to engineer gene delivery vehicles.

keywords

  • AI gene therapy vector design
  • AAV capsid engineering
  • genomic medicine delivery
  • gene therapy payload design
  • tissue specific gene delivery
  • AI cell and gene therapy

voice

  • Scientific and ambitious
  • Collaborative
  • Patient-focused

signals

  • text: A new gene therapy program facing tissue targeting or vector toxicity challenges is a strong partnership trigger.
  • text: A biopharma company announcing a cell and gene therapy collaboration or seeking delivery assets may be evaluating external innovation.

pricing

model: unknown

motion

sales_led

channels

  • scientific conferences
  • partnerships
  • press
  • LinkedIn

confidence

medium

Founders

  • name: David Delbourgo
    title: Founder
    role: Founder
    bio: 23 y of experience in healthcare innovation with multiple executive roles in Business Development, Marketing and Commercial Operations. Former GE Healthcare. MBA Chicago Booth, Biomedical Engineer MS University of Compiègne, France.
  • name: Julien Cottineau
    title: Founder
    role: Founder
    bio: Senior application scientist at Genomic Vision, leading provider of genetic devices and platform Research fellow at Rockefeller Univ & Necker Hospital on human complex immune deficiencies in J-L Casanova’s lab PhD in genetics, molecular biology & immunology at Université Pierre & Marie Curie With Honors

Back to YC companies